There have been tremendous advancements and breakthroughs in cell therapy treatments.  Autologous treatments are extremely effective personalized therapies, but have significant medical, cost and commercialization limitations.  Allogeneic treatments provide us with an opportunity to expand and extend access to personalized therapies to patients in need, but face efficacy, safety, and process hurdles.

While related, the differences are stark, forcing your company to make unique and critical process and business decisions to ensure your company implements the best technologies to execute the most effective autologous and/or allogeneic cell therapy manufacturing strategy.